ArticleQuantitative imaging in medicine and surgery2026
Safety and efficacy of transcatheter arterial infusion chemotherapy combined with Lipiodol chemoembolization for advanced colorectal cancer with bleeding: a retrospective single-center clinical study of 119 patients in China.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC)-related bleeding is a common but challenging problem. This retrospective study evaluates the safety and effectiveness of transcatheter arterial infusion chemotherapy (TAI) combined with Lipiodol chemoembolization (LCE) for advanced CRC with bleeding. Methods: The data of patients with advanced CRC with bleeding (n=119) treated by TAI + LCE were retrospectively analyzed. The clinical efficacy of treatment, adverse events, hematochezia-free survival (HFS), and overall survival (OS) were analyzed. Results: The technical success rate was 100%. No serious per-interventional adverse events occurred. Clinical success was achieved in 99/119 (83.2%) patients. Four patients were withdrawn from the study. Treatment response was graded as complete remission in 19/112 (17.0%) patients, partial remission in 55/112 (49.1%), stable disease in 23/112 (20.5%), and progressive disease in 15/112 (13.4%). The objective response rate and disease control rate were 68.5% and 90.7%, respectively. Among patients who achieved clinical success, median HFS was 11.0 months (95% CI: 8.34-13.66). Age and bleeding time were independent risk factors of recurrent bleeding. Median OS was significantly longer in patients with clinical success than in patients with clinical failure. Conclusions: Transcatheter arterial infusion chemotherapy combined with Lipiodol chemoembolization appears to be a safe, effective, and well-tolerated palliative treatment for advanced CRC with bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.